Regional osteoporosis screening, referral, and monitoring program in community pharmacies: Findings from project ImPACT: Osteoporosis

Journal of the American Pharmacists Association

Volumn 44, Issue 2, 2004, Pages 152-160

  Goode, Jean Venable ^a   Swiger, Kim ^b   Bluml, Benjamin M ^c  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Pharmacy   (United States)

^c AMERICAN PHARMACISTS ASSOCIATION   (United States)

Author keywords

Bone mineral density testing; Collaborative practice; Community health management services; Medication therapy management; Osteoporosis screening; Patient referral; Project ImPACT: Osteoporosis

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; BONE DENSITY; COHORT ANALYSIS; COOPERATION; DRUG EFFECT; ECONOMICS; EVALUATION; FEMALE; FOLLOW UP; HEALTH CARE QUALITY; HEALTH PROMOTION; HUMAN; MASS SCREENING; METHODOLOGY; MIDDLE AGED; ORGANIZATION AND MANAGEMENT; OSTEOPOROSIS; PATIENT REFERRAL; PHARMACY; PROGRAM DEVELOPMENT; RISK FACTOR; STANDARD; TREATMENT OUTCOME; UNITED STATES;

ADOLESCENT; ADULT; AGED; BONE DENSITY; COHORT STUDIES; COMMUNITY PHARMACY SERVICES; COOPERATIVE BEHAVIOR; FEMALE; FOLLOW-UP STUDIES; HEALTH PROMOTION; HUMANS; MASS SCREENING; MIDDLE AGED; OSTEOPOROSIS; PROGRAM DEVELOPMENT; PROGRAM EVALUATION; REFERRAL AND CONSULTATION; RISK FACTORS; TREATMENT OUTCOME; VIRGINIA;

EID: 3042704731     PISSN: 15443191     EISSN: 15443450     Source Type: Journal    
DOI: 10.1331/154434504773062609     Document Type: Article

References (13)

1. National Osteoporosis Foundation. Physician's guide to prevention and treatment of osteoporosis. 2000. Accessed at www.nof.org/physguide, February 5, 2004.
2. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA. 2001;285:785-95.
3. National Osteoporosis Foundation. Disease Statistics. December 2002. Accessed at www.nof.org/osteoporosis/stats.htm, February 5, 2004.
4. American Association of Clinical Endocrinologists. 2001 Medical guidelines for clinical practice for the prevention and management of postmenopausal osteoporosis. Endocr Pract. 2001;7:294-312.
5. Bluml BM, McKenney JM, Cziraky MJ. Pharmaceutical care services and results in Project ImPACT: Hyperlipidemia. J Am Pharm Assoc. 2000;40:157-65.
6. Elliott ME, Meek PD, Kanous NL, et al. Pharmacy-based bone mass measurement to assess osteoporosis risk. Ann Pharmacother. 2002;36:571-7.
7. Farina RD, Corbett AH, Edwards MD, et al. Osteoporosis screening: is screening effective? Can it be done economically? Will people pay for it? US Pharm. 1999;24:38-43.
8. Elliott ME, Meek PD, Kanous NL, et al. Osteoporosis screening by community pharmacists: use of National Osteoporosis Foundation resources. J Am Pharm Assoc. 2002;42:101-10.
9. Lata PF, Brinkley NC, Elliott ME. Acceptability of pharmacy-based bone density measurement by women and primary healthcare providers. Menopause. 2002;9:449-55.
10. Cerulli J, Zeolla M. Impact and feasibility of a community pharmacy bone mineral density screening and education program. J Am Pharm Assoc. 2004;44:161-7.
11. Rolnick SJ, Kopher R, Jackson J, et al. What is the impact of osteoporosis education and bone mineral density testing for postmenopausal women in a managed care setting? Menopause. 2001;8:141-8.
12. Rubin SM, Cummings SR. Results of bone densitometry affect women's decisions about taking measures to prevent fractures. Ann Intern Med. 1992;116:990-5.
13. Holt LH, Taft LB, Moulthrop JM. Bone density measurement: survey of use and impact on treatment. Menopause. 1997;4:219-24.